非小细胞肺癌中CD151及uroplakin 1A表达及临床意义的研究  

Expression and clinical significance of CD151 and uroplakin 1A in non-small cell lung cancer

作　　者：曾赟[1] 王昕炜[1] 尹必俭[1] 沈政洁[2] ZENG Yun;WANG Xinwei;YIN Bijian;SHEN Zhengjie(Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, Jiangsu, China;Department of Medical Oncology, the First People’s Hospital of Zhangjiagang, Zhangjiagang 215600, Jiangsu, China)

机构地区：[1]江苏省肿瘤医院/江苏省肿瘤防治研究所/南京医科大学附属肿瘤医院肿瘤内科,南京210009 [2]张家港市第一人民医院肿瘤内科,江苏张家港2156000

出　　处：《癌症进展》2019年第11期1306-1309,共4页Oncology Progress

摘　　要：目的探讨CD151和uroplakin 1A在非小细胞肺癌(NSCLC)中的表达情况及临床意义。方法选取156例NSCLC患者(NSCLC组)和66例肺良性病变患者(肺良性病变组)。采用免疫组织化学法检测并比较CD151和uroplakin 1A在NSCLC组织和肺部良性病变组织中的表达情况,并分析其与NSCLC患者临床特征、5年生存率的关系。结果NSCLC组织中的CD151和uroplakin 1A阳性表达率均明显高于肺部良性病变组织(P﹤0.01);有吸烟史、TNM分期为Ⅲ~Ⅳ期、有淋巴结转移的NSCLC患者的CD151的阳性表达率均明显高于无吸烟史、TNM分期为Ⅰ~Ⅱ期、无淋巴结转移的NSCLC患者(P﹤0.01);有吸烟史、肿瘤直径﹥2 cm、TNM分期为Ⅲ~Ⅳ期、有淋巴结转移的NSCLC患者的uroplakin 1A的阳性表达率均明显高于无吸烟史、肿瘤直径≤2 cm、TNM分期为Ⅰ~Ⅱ期、无淋巴结转移的患者(P﹤0.01);不同组织分化程度、病理学分型的NSCLC患者的CD151和uroplakin 1A的阳性表达率比较,差异均有统计学意义(P﹤0.01)。CD151及uroplakin 1A同时阳性表达的NSCLC患者80例,同时阴性表达的患者26例,CD151阴性、uroplakin 1A阳性或者CD151阳性、uroplakin 1A阴性的患者50例;CD151阳性表达和uroplakin 1A阳性表达呈正相关(r=0.297,P﹤0.01);CD151和uroplakin 1A同时阳性表达和同时阴性表达的NSCLC患者的5年生存率分别为0和19.2%,CD151阴性、uroplakin 1A阳性或者CD151阳性、uroplakin 1A阴性的NSCLC患者的5年生存率为12.0%;CD151和uroplakin 1A同时阳性表达的NSCLC患者的5年生存率低于上述另两种情况(P﹤0.05)。结论与肺部良性病变比较,NSCLC患者的CD151和uroplakin 1A的阳性表达率更高,且其表达情况与NSCLC患者的临床特征及5年生存率有关,有利于指导多学科综合治疗,可能成为评估NSCLC患者预后的指标。Objective To investigate the expression of CD151 and uroplakin 1A in non-small cell lung cancer(NSCLC)and the relationship with clinical significance.Method 156 cases of NSCLC(NSCLC group)and 66 cases of benign lung lesions(benign lung lesions group)were collected.Immunohistochemical assay was utilized to determine the expression of CD151 and uroplakin 1A in NSCLC and benign lung lesions,additionally,the relationship between CD151 and uroplakin 1A expression and the clinical characteristics and 5-year survival rate among NSCLC patients was investigated.Result The positive expression rates of CD151 and uroplakin 1A in NSCLC tissues were significantly higher than those in benign lung lesions(P<0.01);in NSCLC patients,smoking history,TNM stage III-IV,and positive lymph node metastasis were associated with higher CD151 expression compared to those with no smoking history,TNM stageⅠ-Ⅱdisease,and no lymph node metastasis(P<0.01);besides,NSCLC patients with smoking history,tumor diameter>2 cm,TNM stageⅢ-Ⅳ,and positive lymph node metastasis exhibited significantly higher positive expression rate of uroplakin1A than those without smoking history,tumor diameter≤2 cm,TNM stageⅠ-Ⅱ,and negative lymph node metastasis(P<0.01);degree of differentiation and pathological type were correlated with the positive expression of CD151 and uroplakin 1A among NSCLC patients,with statistically significant differences observed(P<0.01);there were 80 patients with positive expression of both CD151 and uroplakin 1A,26 patients with negative expression at the same time,and 50 patients with CD151 negative,uroplakin 1A positive or CD151 positive and uroplakin 1A negative,indicating a positive correlation between positive expression of CD151 and uroplakin 1A(r=0.297,P<0.01);the 5-year survival rate for patients with positive CD151 and positive uroplakin 1A,or those with negative CD151 and negative uroplakin 1A were 0 and19.2%,respectively,while the 5-year survival rate of patients with negative CD151 and positive uroplakin 1A,or posi

关 键 词：UROPLAKIN 1A CD151 非小细胞肺癌 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]